Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 12.32 AUD -2.69% Market Closed
Market Cap: 1.6B AUD
Have any thoughts about
Neuren Pharmaceuticals Ltd?
Write Note

Intrinsic Value

The intrinsic value of one NEU stock under the Base Case scenario is 8.13 AUD. Compared to the current market price of 12.32 AUD, Neuren Pharmaceuticals Ltd is Overvalued by 34%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NEU Intrinsic Value
8.13 AUD
Overvaluation 34%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Neuren Pharmaceuticals Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NEU cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NEU?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Neuren Pharmaceuticals Ltd

Provide an overview of the primary business activities
of Neuren Pharmaceuticals Ltd.

What unique competitive advantages
does Neuren Pharmaceuticals Ltd hold over its rivals?

What risks and challenges
does Neuren Pharmaceuticals Ltd face in the near future?

Has there been any significant insider trading activity
in Neuren Pharmaceuticals Ltd recently?

Summarize the latest earnings call
of Neuren Pharmaceuticals Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Neuren Pharmaceuticals Ltd.

Provide P/S
for Neuren Pharmaceuticals Ltd.

Provide P/E
for Neuren Pharmaceuticals Ltd.

Provide P/OCF
for Neuren Pharmaceuticals Ltd.

Provide P/FCFE
for Neuren Pharmaceuticals Ltd.

Provide P/B
for Neuren Pharmaceuticals Ltd.

Provide EV/S
for Neuren Pharmaceuticals Ltd.

Provide EV/GP
for Neuren Pharmaceuticals Ltd.

Provide EV/EBITDA
for Neuren Pharmaceuticals Ltd.

Provide EV/EBIT
for Neuren Pharmaceuticals Ltd.

Provide EV/OCF
for Neuren Pharmaceuticals Ltd.

Provide EV/FCFF
for Neuren Pharmaceuticals Ltd.

Provide EV/IC
for Neuren Pharmaceuticals Ltd.

Show me price targets
for Neuren Pharmaceuticals Ltd made by professional analysts.

What are the Revenue projections
for Neuren Pharmaceuticals Ltd?

How accurate were the past Revenue estimates
for Neuren Pharmaceuticals Ltd?

What are the Net Income projections
for Neuren Pharmaceuticals Ltd?

How accurate were the past Net Income estimates
for Neuren Pharmaceuticals Ltd?

What are the EPS projections
for Neuren Pharmaceuticals Ltd?

How accurate were the past EPS estimates
for Neuren Pharmaceuticals Ltd?

What are the EBIT projections
for Neuren Pharmaceuticals Ltd?

How accurate were the past EBIT estimates
for Neuren Pharmaceuticals Ltd?

Compare the revenue forecasts
for Neuren Pharmaceuticals Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Neuren Pharmaceuticals Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Neuren Pharmaceuticals Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Neuren Pharmaceuticals Ltd compared to its peers.

Compare the P/E ratios
of Neuren Pharmaceuticals Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Neuren Pharmaceuticals Ltd with its peers.

Analyze the financial leverage
of Neuren Pharmaceuticals Ltd compared to its main competitors.

Show all profitability ratios
for Neuren Pharmaceuticals Ltd.

Provide ROE
for Neuren Pharmaceuticals Ltd.

Provide ROA
for Neuren Pharmaceuticals Ltd.

Provide ROIC
for Neuren Pharmaceuticals Ltd.

Provide ROCE
for Neuren Pharmaceuticals Ltd.

Provide Gross Margin
for Neuren Pharmaceuticals Ltd.

Provide Operating Margin
for Neuren Pharmaceuticals Ltd.

Provide Net Margin
for Neuren Pharmaceuticals Ltd.

Provide FCF Margin
for Neuren Pharmaceuticals Ltd.

Show all solvency ratios
for Neuren Pharmaceuticals Ltd.

Provide D/E Ratio
for Neuren Pharmaceuticals Ltd.

Provide D/A Ratio
for Neuren Pharmaceuticals Ltd.

Provide Interest Coverage Ratio
for Neuren Pharmaceuticals Ltd.

Provide Altman Z-Score Ratio
for Neuren Pharmaceuticals Ltd.

Provide Quick Ratio
for Neuren Pharmaceuticals Ltd.

Provide Current Ratio
for Neuren Pharmaceuticals Ltd.

Provide Cash Ratio
for Neuren Pharmaceuticals Ltd.

What is the historical Revenue growth
over the last 5 years for Neuren Pharmaceuticals Ltd?

What is the historical Net Income growth
over the last 5 years for Neuren Pharmaceuticals Ltd?

What is the current Free Cash Flow
of Neuren Pharmaceuticals Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Neuren Pharmaceuticals Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Neuren Pharmaceuticals Ltd

Current Assets 228m
Cash & Short-Term Investments 213.2m
Receivables 14.9m
Non-Current Assets 110k
PP&E 35k
Other Non-Current Assets 75k
Current Liabilities 9m
Accounts Payable 4.5m
Other Current Liabilities 4.5m
Non-Current Liabilities 29k
Other Non-Current Liabilities 29k
Efficiency

Earnings Waterfall
Neuren Pharmaceuticals Ltd

Revenue
204.2m AUD
Operating Expenses
-38.2m AUD
Operating Income
166m AUD
Other Expenses
-48.7m AUD
Net Income
117.3m AUD

Free Cash Flow Analysis
Neuren Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Neuren had a remarkable financial year with a profit of AUD 157 million, driven by significant income streams including royalty, milestone payments from DAYBUE sales, and an expanded deal with Acadia. DAYBUE net sales for the year were USD 177 million, surpassing expectations. Guidance for 2024 indicates sales growth to USD 370-420 million, with expected royalty income of AUD 61-70 million. Milestone payments could reach USD 50 million, potentially boosting total revenue to $138 million. Beyond DAYBUE, Neuren's value is also fueled by trofinetide sales and Phase II trial results for NNZ-2591 across four indications.

What is Earnings Call?
Fundamental Scores

NEU Profitability Score
Profitability Due Diligence

Neuren Pharmaceuticals Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional 3-Years Revenue Growth
Exceptional ROE
Exceptional ROIC
59/100
Profitability
Score

Neuren Pharmaceuticals Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

NEU Solvency Score
Solvency Due Diligence

Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NEU Price Targets Summary
Neuren Pharmaceuticals Ltd

Wall Street analysts forecast NEU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NEU is 27.99 AUD with a low forecast of 23.13 AUD and a high forecast of 32.49 AUD.

Lowest
Price Target
23.13 AUD
88% Upside
Average
Price Target
27.99 AUD
127% Upside
Highest
Price Target
32.49 AUD
164% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NEU?

Click here to dive deeper.

Dividends

Neuren Pharmaceuticals Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for NEU is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

NEU Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd

Country

Australia

Industry

Pharmaceuticals

Market Cap

1.6B AUD

Dividend Yield

0%

Description

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The Company’s lead drug compound, Trofinetide, is in a Phase III clinical trial in the United States for Rett syndrome and has completed a Phase II clinical trial in Fragile X syndrome. Its both programs have each received Fast Track designation by the United States Food and Drug Administration (FDA) and Orphan Drug designation in both the United States and the European Union. The firm has granted a license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, while retaining all rights outside North America. The firm is preparing to initiate Phase II trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome. The company is also planning a Phase II trial in Prader-Willi syndrome.

Contact

VICTORIA
Melbourne
SE 201 697 Burke Rd, Camberwell
+61390920480.0
www.neurenpharma.com

IPO

2005-02-03

Employees

-

Officers

CEO, MD & Executive Director
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
CFO & Company Secretary
Ms. Lauren Frazer C.A.
Chief Science Officer
Mr. Lawrence Glass BA (Biology)
Vice President of Corporate Development
Mr. Gerry Zhao
Chief Medical Officer
Dr. Liza A. Squires M.D.

See Also

Discover More
What is the Intrinsic Value of one NEU stock?

The intrinsic value of one NEU stock under the Base Case scenario is 8.13 AUD.

Is NEU stock undervalued or overvalued?

Compared to the current market price of 12.32 AUD, Neuren Pharmaceuticals Ltd is Overvalued by 34%.

Back to Top